过去一周（截至5月8日收盘），A股市场震荡上行。医药ETF（512120）下跌1.32%，港股通生物科技ETF(159102)下跌1%。相关个股方面，恒瑞医药下跌2%，药明康德下跌2.51%，百济神州上涨9.79%。 消息面上，恒瑞医药公告称，公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意HRS-3005片在B细胞恶性肿瘤中开展临床试验。该药物为公司自主研发的创新型抗肿瘤药，目前...
Source Link过去一周（截至5月8日收盘），A股市场震荡上行。医药ETF（512120）下跌1.32%，港股通生物科技ETF(159102)下跌1%。相关个股方面，恒瑞医药下跌2%，药明康德下跌2.51%，百济神州上涨9.79%。 消息面上，恒瑞医药公告称，公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意HRS-3005片在B细胞恶性肿瘤中开展临床试验。该药物为公司自主研发的创新型抗肿瘤药，目前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.